Literature DB >> 21196539

Birmingham hip resurfacing: a minimum follow-up of ten years.

R B C Treacy1, C W McBryde, E Shears, P B Pynsent.   

Abstract

We report the survival, radiological and functional outcomes of a single surgeon series of his first 144 consecutive Birmingham hip resurfacing procedures (130 patients) at a minimum of ten years. There were ten revisions during this time. Although no patients were lost to follow-up some did not complete the scoring assessment or undergo radiological assessment at ten years. The ten-year survival for male patients was 98.0% (95% confidence interval 95.2 to 100). The ten-year survival for the total cohort with aseptic revision as the endpoint was 95.5% (95% confidence interval 91.8 to 99.0) and including revisions for sepsis was 93.5% (95% confidence interval 89.2 to 97.6). The median modified Oxford hip score at ten years was 4.2% (interquartile range 0 to 19) and the median University of California, Los Angeles score was 7.0 (interquartile range 5.0 to 8.0). This study confirms the midterm reports that metal-on-metal hip resurfacing using the Birmingham Hip provides a durable alternative to total hip replacement, particularly in younger male patients wishing to maintain a high level of function, with low risk of revision for at least ten years.

Entities:  

Mesh:

Year:  2011        PMID: 21196539     DOI: 10.1302/0301-620X.93B1.24134

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  47 in total

1.  Revision rate of Birmingham Hip Resurfacing arthroplasty: comparison of published literature and arthroplasty register data.

Authors:  Reinhard Schuh; Daniel Neumann; Rauend Rauf; Jochen Hofstaetter; Nikolaus Boehler; Gerold Labek
Journal:  Int Orthop       Date:  2012-02-22       Impact factor: 3.075

Review 2.  Surgical management of hip osteoarthritis.

Authors:  Rajiv Gandhi; Anthony V Perruccio; Nizar N Mahomed
Journal:  CMAJ       Date:  2013-10-21       Impact factor: 8.262

3.  Intramedullary fixation of pertrochanteric fractures after hip resurfacing arthroplasty - Do we have the answer? Case report and literature review.

Authors:  Samik Banerjee; Timothy Little; Nicholas Little
Journal:  J Orthop       Date:  2014-01-29

Review 4.  The role of ultrasound in the assessment of post-operative complications following hip arthroplasty.

Authors:  H Douis; D J Dunlop; A M Pearson; J N O'Hara; S L J James
Journal:  Skeletal Radiol       Date:  2012-03-17       Impact factor: 2.199

5.  Letter to the editor: the withdrawn ASR™ THA and hip resurfacing systems: how have our patients fared over 1 to 6 years?

Authors:  Harlan C Amstutz; Michel J Le Duff
Journal:  Clin Orthop Relat Res       Date:  2013-01       Impact factor: 4.176

6.  Can patients return to high-impact physical activities after hip resurfacing? A prospective study.

Authors:  Julien Girard; Bruno Miletic; Anthony Deny; Henri Migaud; Nicolas Fouilleron
Journal:  Int Orthop       Date:  2013-03-02       Impact factor: 3.075

7.  The gait of patients with one resurfacing and one replacement hip: a single blinded controlled study.

Authors:  Adeel Aqil; Roshan Drabu; Jeroen H Bergmann; Milad Masjedi; Victoria Manning; Barry Andrews; Sarah K Muirhead-Allwood; Justin P Cobb
Journal:  Int Orthop       Date:  2013-02-27       Impact factor: 3.075

8.  Patients report improvement in quality of life and satisfaction after hip resurfacing arthroplasty.

Authors:  Wael A Rahman; Nelson V Greidanus; Alexander Siegmeth; Bassam A Masri; Clive P Duncan; Donald S Garbuz
Journal:  Clin Orthop Relat Res       Date:  2013-02       Impact factor: 4.176

Review 9.  Metal-on-metal hip resurfacing arthroplasty: an analysis of safety and revision rates.

Authors:  S Sehatzadeh; K Kaulback; L Levin
Journal:  Ont Health Technol Assess Ser       Date:  2012-08-01

10.  Long-term results of Birmingham hip resurfacing arthroplasty in Asian patients.

Authors:  Keisuke Uemura; Masaki Takao; Hidetoshi Hamada; Takashi Sakai; Kenji Ohzono; Nobuhiko Sugano
Journal:  J Artif Organs       Date:  2017-08-30       Impact factor: 1.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.